Determining the Effectiveness of MS Treatments

A short video summarising the key findings of a recent paper, titled “Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing-remitting multiple sclerosis“.

In this study, scientists from the Universitätsspital Basel (University Hospital Basel), University of California, Ottawa University and the University of Siena discussed using measurements of both neuroinflammation and neurodegeneration to determine the effectiveness of multiple sclerosis treatments.

Using Gilenya as an example, they showed that a key benefit was reducing the amount of brain atrophy, which has been closely linked to disease progression.

Those wishing to read the published abstract of this study can do so here.